Related Experiment Video
Updated: Jul 14, 2026
06:12
Using Nicotine in a Silica-Exposed Mouse Model to Promote Lung Epithelial-Mesenchymal Transition
Published on: March 3, 2023
Varenicline: the newest agent for smoking cessation
Lisa A Potts1, Candice L Garwood
1Department of Pharmacy, Cleveland Clinic, Cleveland, OH 44195, USA. pottsl@ccf.org
Summary
Varenicline is a new smoking cessation therapy that partially activates nicotinic receptors, significantly improving quit rates compared to bupropion and placebo. It is well-tolerated and offers a new option for smokers.
Area of Science:
- Pharmacology and Therapeutics
- Addiction Medicine
- Clinical Trials
Background:
- Smoking cessation remains a significant public health challenge.
- Nicotine addiction is a complex neurobiological process.
- Existing therapies have limitations in efficacy and tolerability.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, clinical efficacy, safety, dosage, administration, and therapeutic role of varenicline.
- To evaluate varenicline as a novel smoking cessation aid.
Main Methods:
- Review of published Phase III clinical trials.
- Pharmacological and pharmacokinetic assessment of varenicline.
- Safety and tolerability data analysis.
Main Results:
- Varenicline selectively targets alpha4beta2 nicotinic acetylcholine receptors as a partial agonist.
- Pooled data from two trials showed significantly higher continuous quit rates with varenicline (44.2%) versus bupropion (29.7%) and placebo (17.7%).
- A third trial confirmed higher quit rates with varenicline compared to placebo; it is generally well-tolerated with no significant drug interactions.
Conclusions:
- Varenicline represents a novel pharmacological approach to smoking cessation by targeting nicotine addiction neurobiology.
- It offers a new therapeutic option for patients unable to tolerate or contraindicated for other cessation therapies.
- Varenicline demonstrates superior efficacy and favorable tolerability for smoking cessation.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:29Stimulants
Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:30Adrenergic Agonists: Direct-Acting Agents
Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
These agents can be classified...
These agents can be classified...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:25Adrenergic Agonists: Indirect-Acting Agents
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...